Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

Mako Medical expands COVID-19 testing to help those on the front lines

Mako Medical expands COVID-19 testing to help those on the front lines

Mako Medical and Mako Medical Laboratories has been working around the clock to expand capacity and testing for COVID-19. As demands continue to soar, the average turnaround time with many laboratories in America is well over one week. Many states are still on lockdown with active-shelter-in-place orders. Access to testing is difficult for many parts of the country, as swabs, PPE, and other vital supplies that go with the test have become hard to find and are on backorder.

Mako Medical and its team of scientists have expanded testing capacity, have added additional staff, additional instrumentation, and utilized automation to help increase its current capacity. These measures allow for increased capacity and accelerated turnaround times.

Mako Medical has also chosen to focus on front-line healthcare workers and first responders. This has allowed hospitals to continue procedures, emergency medical staff to continue practicing, and ease fears for many medical staff that are still treating patients with chronic conditions. With increased demand for testing, it was getting harder and harder to test those working in healthcare and seeing patients.

“Turnaround time is extremely important, so everything we do is focused on maintaining 24-hour turnaround on all the testing we are running,” said Josh Arant COO of Mako Medical and Mako Medical Laboratories. “Mako Medical’s dedication to those on the front lines allows medical procedures to continue without having to sideline a doctor for 14 days for quarantine. If a doctor comes in contact with someone or suspects they have contracted the virus, we can have results back in less than 24 hours and doctors back in the hospital seeing patients,” said Arant.

Mako Medical has also made the transition to antibody testing as it prepares to ramp up for an increased demand by states wanting to begin reopening the economy. Mako Medical hopes this antibody test will help provide insight to who has had the virus already and how to continue testing those who have not.

Mako Medical and Mako Medical Laboratories is an awarding-winning healthcare company focused on laboratory testing and pharmacy services. Mako Medical is known for its use of robotics, automation, and leveraging technology. Mako Medical also hires military veterans for many of its positions and supports many nonprofits and charities.

ABM Respiratory Care creates world’s first IOT-enabled Tele-Ventilator for COVID-19 Pandemic

Singapore based ABM Respiratory Care, a medical device company focused on the development and commercialization of airway clearance and ventilation solutions has developed an innovative ventilator which helps healthcare professionals monitor and program the device from anywhere in the world in real-time. ABM is preparing for fast-track approval of its Tele-Ventilator with regulatory agencies in several countries, including Singapore.

The COVID-19 pandemic has highlighted a shortage of ventilators but also a shortage of trained healthcare professionals to manage the large volume of ventilators when needed. In addition, frequent bedside visits by healthcare professionals to adjust and monitor ventilators increase the possibility of infection thereby pushing an already fragile healthcare system into a further grim situation. ABM’s Tele-Ventilator addresses both issues by enabling healthcare professionals to securely monitor and adjust ventilator settings through their online portal from any location.

“Tele access enabled infrastructure will see a lot of value in the present scenario where healthcare arena has been overburdened because of unprecedented demand. Singapore is the hub for technology and healthcare innovations. We appreciate the Government’s proactive and transparent approach in protecting the health of its people and this technology will surely be much-needed support to front-line healthcare staff and caregivers during such critical times”, said Vinay Joshi, ABM CEO.

ABM’s Tele-Ventilator leverages new technology which is 25 times faster and creates 50 times less data traffic than traditional web technologies. This enables time-valuable, responsive, consistent telemetry and large-scale secure access to ventilators without a complex configuration which is usually needed in traditional connectivity systems.

“Manufacturers will eventually stand up to the challenge of meeting ventilator demand for the current situation but unlike machines, skilled respiratory staff cannot be cloned at the required pace,” said Vinay Joshi, ABM CEO. Our tele-ventilation solution will augment access to a trained healthcare professional and increase their reach to save lives not only within the hospital network but even in most remote parts of the globe”.

ABM’s Tele-Ventilator, branded as BiWaze™ ION, is based on its BiWaze™ platform developed over the last 30 months and has already US FDA-510(K)-cleared their BiWaze™ Cough system. BiWaze™ ION can be used in both Invasive and Non-Invasive modes and can be deployed in an ICU, ambulatory or subacute settings for pediatric and adult patients. BiWaze™ ION is a 4 kg, battery-operated, touchscreen-based ventilator which includes advanced ventilator modes as well as key safety and alarm features as per international regulatory standards.

Chad Boerst, Founder and President of ABM Respiratory, said, “Manufacturers around the world are facing difficulty in scaling-up production because of complex mechanical designs which impose huge challenges to secure parts and time to build ventilators. BiWaze™ ION is easy to manufacture and the supply chain is already being streamlined to scale-up production significantly in the coming months”.

Oxford University Imaging Lab and Zegami comes together to target Cardiovascular disease

Oxford University Imaging Lab and Zegami comes together to target Cardiovascular disease

Zegami, the data visualisation company, has been appointed by Oxford University researchers at the Oxford Cardiovascular Clinical Research Facility to accelerate research into cardiovascular disease.

The team will do this by applying data visualisation techniques developed by Zegami to hundreds of thousands of images of the heart, making it easier to categorise them and identify new trends and patterns.

Cardiovascular imaging yields large data sets, both for image analysis as well as incorporation with other clinical data.  Most medical images today are stored in digital formats as pixels or voxels describing a small area or volume. Millions of pixels or voxels form one image, and data visualisation techniques can help analyse this more effectively.

Zegami helps scientists, researchers and academics to make sense of their data with intuitive, engaging image-based software which converts spreadsheets and complicated datasets into a visual platform that is easy to navigate and interact with. Not only does this provide medical researchers with a unique way to study the cardiovascular health of thousands of different patients at the same time, the insights generated through data visualisation could support development of machine learning algorithms that identify and predict heart disease in patients.

Cristiana Monteiro, Head of the Oxford Research Echocardiography Core Laboratory, said: “Heart and circulatory diseases cause more than a quarter of all deaths in the UK, and some 7.4 million people are living with cardiovascular conditions. We support and manage some of the largest cardiovascular trials and studies in the world, involving multiple different hospitals and countries, and millions of images. We believe data visualisation tools could address many of the problems we face trying to navigate and make sense of these large complex imaging datasets, allowing researchers to generate faster insights and results.”

Steve Taylor, Chief Scientific Officer at Zegami and Oxford University researcher, said: “Advances in technology means the medical profession can take more images relating to cardiovascular issues than ever before, and the information captured in these can help detect heart and circulatory problems in patients more quickly, improve treatment levels and the overall quality of life of millions of people.  We are delighted to be working with the Oxford University researchers in this area.  The medical industry is making much greater use of digital visualisation tools, and this is a huge growth market for us.”

Prospero Health Partners With GrandPad to Improve Access to Care for Vulnerable Seniors During COVID-19 Surge

Prospero Health Partners With GrandPad to Improve Access to Care for Vulnerable Seniors During COVID-19 Surge

Prospero Health, a team-based home health care company, has partnered with GrandPad, the first purpose-built tablet for people over 75, to improve access to care for vulnerable seniors during the COVID-19 crisis. Nearly 100 Prospero patients are already engaging in live video interactions with their care teams using GrandPad, allowing Prospero to continue bringing comprehensive and compassionate care to patients’ homes while adhering to strict social distancing guidelines.

The COVID-19 risk to elderly and immuno-suppressed patients has isolated many in their homes, making it harder for clinicians and caregivers to attend to their medical and emotional well-being. From the potential for missed medications and falls to the risk of anxiety and confusion, these patients require even greater vigilance during this global crisis. Prior to this partnership, more than 80% of Prospero patients did not have access to a mobile device with video chat capabilities. Utilizing GrandPads addresses that barrier to access and allows Prospero care providers to continue visual observations that enable better identification of symptoms and behaviors than with traditional telephone interactions.

The partnership with GrandPad provides an immediate boost to Prospero’s telemedicine capabilities. “Our care model has been evolving to bring more virtual capabilities into the home, and the COVID-19 pandemic has accelerated that effort,” said Doug Wenners, Co-Founder and CEO of Prospero. “While there’s no substitute for home-based visits, this crisis shows how important it is to provide other ways to engage with patients, and thanks to GrandPad we’ve been able to quickly mobilize.”

Prospero’s clinical care model consists of multi-disciplinary teams of doctors, nurses and social workers who provide care in the home and through 24/7 telemedicine support. The GrandPad tablet is customized for ease of use by seniors and allows Prospero care teams to regularly check in on patients and collaborate with external specialists, primary care physicians and family caregivers. These connections are also essential for preventing loneliness, which can exacerbate existing clinical conditions for older adults. In-home care will still be available when clinically necessary.

Reconnecting seniors with caregivers and family members is critically important to maintaining physical and mental health during social distancing,” said Scott Lien, Co-Founder and CEO of GrandPad. “Innovative healthcare companies like Prospero recognize the role technology can play in bridging this gap with telemedicine capabilities that support consistent access to care, clinical outcomes, and above all, quality of life.”

Prospero is committed to utilizing GrandPads to deliver care to at least 900 patients in the weeks ahead.

About Prospero Health

Prospero Health is a team-based home health care company providing compassionate care and support for a growing population of people living with serious health conditions. Prospero’s multi-disciplinary care teams of doctors, nurses and social workers are specially trained to address complex medical needs, providing face-to-face and virtual telemedicine care in the home at scheduled appointments and anytime unexpected needs arise. Prospero serves patient communities in Connecticut, Georgia, Illinois, Missouri, New Jersey, New York, North Carolina and Philadelphia. For more information, please visit www.prospero-health.com.

About GrandPad

Based in Orange, California USA GrandPad is a privately held company on a mission to improve the lives of millions of seniors by reconnecting them with family, friends, and caregivers. The GrandPad — the first tablet specifically designed for seniors — comes ready to use out of the box and features a secure private family network and premium US-based customer service. There are no confusing buttons, no passwords or pop-up ads, and wireless connectivity and security are built into the device — eliminating the risks of scams and hacks. Users can play games, listen to music, and enjoy many other exclusive apps on the GrandPad. Additionally, caregivers/family members can video chat, receive voice emails, and share photos with the older person through GrandPad’s companion app on i0S and Android.

IMU Collaborates with Fusionex to Integrate Digital Technologies to Enhance Medical Education and Research

IMU Collaborates with Fusionex to Integrate Digital Technologies to Enhance Medical Education and Research

Leading multi-award-winning data technology specialist Fusionex in collaboration with Malaysia’s pioneer private medical and health sciences education institution International Medical University (IMU) incorporates cutting-edge digital technologies into the university’s undergraduate programs in an initiative to support the increased demand for digital heath as a direct result of the Covid-19 pandemic.

Both parties have expressed their total commitment to this initiative through the signing of a Memorandum of Agreement (MoA) between IMU Deputy Vice-Chancellor Professor Peter Pook and Fusionex Group CEO Dato’ Seri Ivan Teh during the Healthcare Big Data Analytics Forum.

This collaboration will see Fusionex’s Big Data Analytics and Artificial Intelligence (AI) being implemented in various aspects of medical research and development to offer invaluable insights, reduce diagnostic and treatment periods, and expedite breakthroughs in medical research. These digital approaches to the medical field will allow students and educators to stay up-to-date regarding the spread of disease, receive better and more rapid health education, maintain consistent communication and improve decision making based on smart and holistic insights.

In order to furnish future healthcare providers with the right set of skills and knowledge, the collaboration will see cutting-edge data technologies being integrated into five IMU undergraduate programs. These programs are Bachelor of Pharmacy (Hons), BSc (Hons) in Medical Biotechnology, BSc (Hons) in Dietetics with Nutrition, BSc (Hons) in Nutrition, and BSc (Hons) in Biomedical Science. These programs will provide four outcomes: an overview of the analytics life cycle, how analytics is contributing to the healthcare industry, why making data-driven decisions is key for an organization, and how the effective use of analytical and AI skills can solve healthcare-related problems.

In addition, the MoA will allow Fusionex to provide trainers, data scientists and subject matter experts to educate and aid IMU remotely through Fusionex Academy. This move will equip and expose the faculty to the advantages of Big Data via in-depth lessons and practical applications for cultivating next-generation digital health experts.

“Confronted with the Covid-19 crisis, healthcare is moving swiftly towards a greater use of sophisticated and purposive digital technologies. Through its utilization, there is no doubt that it would greatly help the medical field overcome any mass health crisis that may erupt, such as the Coronavirus pandemic that we are facing now. As such, we are fully committed to partnering with IMU to nurture future healthcare providers who are able to make full use of innovative technology to save lives,” said Fusionex Group CEO Dato’ Seri Ivan Teh.

About Fusionex

Fusionex is an established multi award-winning data technology provider specializing in Analytics, Big Data, IR 4.0, Machine Learning, and Artificial Intelligence. Its offerings are focused on helping clients unlock value and derive insights from data. Featured on Forbes, Bloomberg, Gartner, IDC, Forrester, Edison and Huffington Post, Fusionex is the largest Big Data Analytics company and market leader in ASEAN, bringing state-of-the-art, innovative and breakthrough data-driven platforms to its stable of clientele (including Fortune 500, FTSE companies, large conglomerates as well as a wide array of small and medium enterprises (SMEs)) that spans across the United States, Europe as well as Asia Pacific. Fusionex is also an MDEC GAIN company as well as an MGS recipient.

Gartner’s 2018 report on Modern Analytics and Business Intelligence shortlisted and commended Fusionex’s data technology platform. In addition, Fusionex has been as identified as a Major Player in IDC’s MarketScape Report for Big Data & Analytics. Fusionex is the only ASEAN-based company to be featured in both reports, cementing its credentials in the data technology market for this region.

To learn more about Fusionex, visit www.fusionex-international.com

Vibra Health Laboratory Scales its Operation to Support COVID-19 Testing with Rapid Turnaround Time

Vibra Health Laboratory Scales its Operation to Support COVID-19 Testing with Rapid Turnaround Time

Vibra Health Laboratory formally announced availability of its high-throughput COVID-19 diagnostic testing services to support Michigan’s private physician and hospital community as well as its national partners in need of rapid and accurate testing for their patients and staff.

Responding to the community’s immediate need for rapid testing and following the US Food and Drug Administration’s (FDA) announcement to grant Emergency Use Authorization (EUA) to the Thermo Fisher 7500DX Platform protocol, VHL launched its COVID-19 Real Time PCR multiplex assay; a qualitative test for the detection of SARS-CoV-2 RNA present in respiratory tract specimens of suspected infected patients.

This assay targets three different viral genomic regions within the SARS-CoV-2 viral genome, a superior choice over targeting a single region used in other tests; therefore, reducing the risk of false negatives. These target regions have undergone bioinformatic selection and analysis to specifically target sequences that are unique to SARS-CoV-2 as determined by the latest available reference genome; therefore, reducing the risk of false positive results.

VHL leverages its ultra-high-throughput instruments and 384-well plate setup strategy to enable 4X the throughput of the standard 96-well plate runs. Higher throughput capabilities enable VHL to run each patient specimen in duplicate; ensuring more accurate results, while simultaneously allowing rapid 24-hour turn-around-time, even as the specimen volume reaches its anticipated apex of COVID-19 cases in Michigan. The lab is expected to continue to ramp up its testing capacity by adding additional equipment and technical personnel in the coming days.

Following Michigan’s “Stay Home, Stay Safe” executive order, VHL was deemed an essential infrastructure business. The team quickly adapted its operations to implement appropriate social distancing practices and disinfecting protocols to ensure safety of its employees and customers. “VHL is dedicated to supporting its local community through this life-threatening pandemic. During this unprecedented time, we are humbled and honored to serve our community and healthcare partners,” said Brad Hollinger, President and CEO of Vibra Healthcare. “The current situation compelled us to shift our primary focus of the lab to scale our facility to match the testing needs of our community.”

VHL continues to support its toxicology and other molecular testing services to ensure no lapse in quality of care for its customers and partners. VHL is a CLIA/COLA Accredited facility, meeting federal clinical laboratory standards.

About Vibra Health Laboratory

Vibra Health Laboratory (VHL) is a full-service CLIA/COLA certified specialty diagnostic laboratory based in Troy, Michigan.

Community Health Systems Announces Definitive Agreement to Sell San Angelo, Texas Hospital

Wanda Group, UPMC to develop and co-manage network of international hospitals in China

Community Health Systems, Inc. announced that a subsidiary of the Company has signed a definitive agreement to sell 171-bed San Angelo Community Medical Center in San Angelo, Texas, and its associated assets to subsidiaries of Shannon Health System.

The parties intend to apply for a Certificate of Public Advantage under a new regulatory framework in the State of Texas, involving, among other things, review and approval of the transaction by the Texas Health and Human Services Commission. This regulatory review process is expected to conclude by the end of the third quarter this year.

The hospital in this transaction is among the additional planned divestitures discussed on the Company’s fourth quarter 2019 earnings call.

About Community Health Systems, Inc.

Community Health Systems, Inc. is one of the largest publicly traded hospital companies in the United States and a leading operator of general acute care hospitals in communities across the country. The Company, through its subsidiaries, owns, leases or operates 99 affiliated hospitals in 17 states with an aggregate of approximately 16,000 licensed beds. The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.”

FDA Grants NEXUS Aortic Arch Stent Graft System Breakthrough Designation

FDA Grants NEXUS Aortic Arch Stent Graft System Breakthrough Designation

Endospan, a pioneer in off-the-shelf endovascular repair of aortic arch disease was recently granted Breakthrough Device Designation from the U.S. FDA for the NEXUS Aortic Arch Stent Graft System.

The FDA’s Breakthrough Device Designation Program is intended to provide timely access to medical devices that have the potential to provide a more effective treatment for life-threatening or irreversibly debilitating diseases or conditions by prioritizing review of its regulatory submissions, thereby expediting the device development process. The designation of NEXUSTM Aortic Arch Stent Graft System as a breakthrough device acknowledges the unmet need in this patient population and the potential for improvements over current standard treatments.

Minimally invasive techniques are standard-of-care for treating descending aortic disease and heart disease, but highly invasive, high-mortality open surgery is still being used in the difficult-to-treat aortic arch anatomy. The NEXUS™ Aortic Arch Stent Graft System is uniquely engineered to address this significant area of unmet clinical need. More than 120,000 patients suffer thoracic aortic arch disease every year in the USA and Europe, with only about 25% being diagnosed or treated. This global market opportunity is over $1.3 billion in a high average selling segment with no other off-the-shelf competition to the NEXUS™ technology.

“Receiving the Breakthrough Device Designation from FDA acknowledges our novel technology has the potential to provide a unique and innovative endovascular treatment for patients with aortic arch disease”, said Kevin Mayberry, CEO of Endospan. “This recognition is important for Endospan in that it allows FDA to expedite the review of an Investigational Device Exemption (IDE) study for the NEXUS Stent Graft System that is expected to start enrolling patients later in 2020. It will also allow prioritized review of a subsequent Pre-Market Approval (PMA) application at the conclusion of the study to seek approval to commercialize the device in the U.S.”

About Endospan
Privately held Endospan, headquartered in Herzlia (Tel Aviv), Israel, is a pioneer in the endovascular repair of aortic arch disease including aneurysms and dissections. Endospan’s NEXUSTM Aortic Arch Stent Graft System is the first endovascular off-the-shelf system with CE Mark to treat a greatly underserved group of patients diagnosed with a dilative lesion in, or near the aortic arch. While minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA), Aortic Arch Disease patients with aneurysms or dissections have not been as fortunate and have had little choice but to undergo open-chest surgery with its invasiveness and risks, lengthy hospitalization periods, and prolonged recuperation.

Renesas Electronics Creates Open-Source Ventilator System Reference Design to Fight COVID-19 Pandemic

Renesas Electronics Creates Open-Source Ventilator System Reference Design to Fight COVID-19 Pandemic

Renesas Electronics Corporation , a premier supplier of advanced semiconductor solutions, introduced a new open-source ventilator system reference design that customers can use to swiftly design ready-to-assemble boards for medical ventilators. Many regions are experiencing a critical shortage of ventilators as COVID-19 infections continue to rise and hospital demand exceeds supply.

“Renesas’ engineers have created a ventilator system reference design to address the challenges our global community faces as we fight the COVID-19 pandemic,” said Chris Allexandre, Senior Vice President, IoT and Infrastructure Business Unit at Renesas. “Leveraging our broad product portfolio and system design expertise, we are enabling customers to accelerate their development of medical ventilator systems capable of operating in a home or hospital environment.”

Renesas’ engineers have followed several open-source ventilator designs, including the Medtronic PB560, to come up with an easy to assemble three board ventilator design. It controls the tidal volume and mixture of gas delivered to the patient while monitoring the patient’s status. The ventilator is portable and can be used with or without gas tanks. In addition, a humidifier can be connected to the ventilator’s intake path to soothe the patient’s breathing, making it more comfortable to be connected for long durations.

The reference design uses 20 Renesas ICs, consisting of microcontroller (MCU), power, and analog ICs that address many of the ventilator’s signal chain electrical functions. The system design implements a sensor board, a motor control board, and features Bluetooth® connectivity that allows medical professionals to monitor several patients simultaneously via a tablet or other mobile device. Each board has a microcontroller (MCU) to control its specific task while monitoring the status of the connecting board. The ventilator solution also provides a system of checks and balances to enable regulatory approval and provide patient safety.

For more information, please visit: Renesas ventilator system reference design.

Renesas is committed to developing innovative solutions that address the challenges our customers face. Learn more about the Renesas solutions used in equipment critical for fighting the life-threatening coronavirus: www.renesas.com/about/press-center/covid-19.
About Renesas Electronics Corporation

Renesas Electronics Corporation delivers trusted embedded design innovation with complete semiconductor solutions that enable billions of connected, intelligent devices to enhance the way people work and live. A global leader in microcontrollers, analog, power, and SoC products, Renesas provides comprehensive solutions for a broad range of automotive, industrial, home electronics, office automation, and information communication technology applications that help shape a limitless future.

Next-Generation Microscopy Image Analysis with Deep-Learning Technology

Next-Generation Microscopy Image Analysis with Deep-Learning Technology

Leveraging the power of deep learning, Olympus cellSens imaging software for microscopy offers significantly improved segmentation analysis, such as label-free nucleus detection and cell counting, for more accurate data and efficient experiments.

Image analysis is a critical part of many life science applications. Analyses that rely on segmentation to extract targets, such as cells and organelles, from the rest of the image are commonplace. However, conventional thresholding methods that depend on brightness and color can miss critical information or may not be able to detect the targets at all. cellSens software’s deep-learning technology enables users to quickly train the system to automatically capture this information, improving the speed and accuracy of label-free object detection, quantitative analysis of fluorescent-labeled cells and segmentation based on morphological features.

Improve Experiment Efficiency with Label-Free Nuclei Detection

The fluorescent staining and UV excitation required for conventional nucleus detection is time consuming and can damage the cells. However, cellSens software can identify and segment nuclei from simple transmission images so that fluorescent labeling is not required.

Reducing Phototoxicity During Fluorescence Imaging to Support Accurate Data Acquisition

With cellSens software’s deep-learning technology, users can get accurate analysis data from low signal-to-noise ratio images. The technology produces outstanding accuracy while significantly reducing the amount of excitation light the cells are exposed to. This enables high-resolution segmentation while helping keep the cells healthy.

Save Time by Automating Cell Counting and Measuring

Deep-learning technology saves time by identifying and counting mitotic cells automatically. This technology is also useful for segmenting images of tissue specimens, such as kidney glomeruli, which is challenging when using conventional methods.

1...626627628...1,125Page 627 of 1,125

About us

Hospital & healthcare Management is a leading B2B arena designed for the healthcare sector, it allow members to reach both ends of the healthcare facility procurement chain. . . Read More

Subscribe us

System

Resources

Archive Links

Subscribe

Copyright © 2008 - 2026 Hospital & Healthcare Management. All rights reserved. Publication of Leo Marcom Pvt Ltd.

Translate »